IsoRay seeds implanted into human prostate for first time; shares spike


IsoRay (ISR) shares jump 12.9% after the company says that its Cesium-131 seeds have been inserted into a human prostate for the first time.

Steven Frank of the Anderson Cancer Center, who performed the implant, said that with its short half-life, Cesium-131 "offers rapid resolution of the acute side effects that can be associated with prostate treatment with brachytherapy".

IsoRay's technology enables doctors to directly place radiation in areas where cancer is most likely to remain after a tumor is removed. (PR)

Comments (1)
  • LynNorstad
    , contributor
    Comment (1) | Send Message
     
    This is incorrect. I had ISR Cesium 131 implants 6 years ago, and I was not the first.

     

    You left out one very important detail ...

     

    This was the first human prostate implantation in combination with C4 Imaging's Sirius positive signal MRI markers.
    8 Apr 2014, 12:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs